Clinical Trial Update: Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen [Phase 3]

View source ↗

Summary

Phase 3 study evaluating sofosbuvir/velpatasvir with ribavirin for 12 or 24 weeks in chronic hepatitis C genotype 1 or 2 patients who failed prior DAA therapy; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Ribavirin (ribavirin)
• Sofosbuvir/Velpatasvir (sofosbuvir/velpatasvir)

Snippet

Sponsor: Gilead Sciences | Conditions: Hepatitis C Virus Infection | Phase 3 | Status: COMPLETED | Results posted: 2018-07-03